Results 101 to 110 of about 1,617,487 (313)

Good clinical practice regulatory inspections: Lessons for Indian investigator sites

Perspectives in Clinical Research, 2010
Regulatory inspections are important to evaluate the integrity of the data submitted to health authorities (HAs), protect patient safety, and assess adequacy of site/sponsor quality systems to achieve the same.
R Marwah, K Van de Voorde, J Parchman
doaj   +1 more source

Children's Databases - Safety and Privacy [PDF]

, 2006
This report describes in detail the policy background, the systems that are being built, the problems with them, and the legal situation in the UK. An appendix looks at Europe, and examines in particular detail how France and Germany have dealt with ...
Anderson, R, Brown, I, Clayton, R, Dowty, T, Korff, D, Munro, E   +5 more
core  

Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication

Molecular Oncology, EarlyView.
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice, Jose I. Lopez, Aitziber Ugalde‐Olano, Maite Zufiaurre, Ianire Astobiza, Natalia Martin‐Martin, Laura Bozal‐Basterra, Saioa Garcia‐Longarte, Amaia Zabala‐Letona, Sofia Rey, Aida Santos‐Martin, Miguel Unda, Ana Loizaga‐Iriarte, Mariona Graupera, Paolo Nuciforo, Arkaitz Carracedo, Isabel Mendizabal   +16 more
wiley   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Leveraging patient experience data to guide medicines development, regulation, access decisions and clinical care in the EU

Frontiers in Medicine
Patient experience data (PED), provided by patients/their carers without interpretation by clinicians, directly capture what matters more to patients on their medical condition, treatment and impact of healthcare.
Diogo Almeida, Diogo Almeida, Denise Umuhire, Rosa Gonzalez-Quevedo, Ana António, Juan Garcia Burgos, Patrice Verpillat, Nathalie Bere, Bruno Sepodes, Bruno Sepodes, Carla Torre, Carla Torre   +11 more
doaj   +1 more source

The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials

Health Technology Assessment, 2014
Background: Pragmatic trials compare the effects of different decisions in usual clinical practice. Objectives: To develop and evaluate methods to implement simple pragmatic trials using routinely collected
Tjeerd-Pieter van Staa, Lisa Dyson, Gerard McCann, Shivani Padmanabhan, Rabah Belatri, Ben Goldacre, Jackie Cassell, Munir Pirmohamed, David Torgerson, Sarah Ronaldson, Joy Adamson, Adel Taweel, Brendan Delaney, Samhar Mahmood, Simona Baracaia, Thomas Round, Robin Fox, Tommy Hunter, Martin Gulliford, Liam Smeeth   +19 more
doaj   +1 more source

Manufacturing the EU Energy Markets. The Current Dynamics of Regulatory Practice [PDF]

This chapter aims to analysis the new dynamics at work in EU energy regulation. Since the publication of the European Commission’s ‘Sector Inquiry Report’ in January 2007, European energy companies have felt the cold wind of competition law - many for ...
Adrien de Hauteclocque, Leigh Hancher
core  

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Extemporaneous Compounding Practice for Dermatologic Preparations in Ethiopian Public Hospitals: Regulatory Requirements and Quality Concerns

Risk Management and Healthcare Policy, 2021
Muluken Nigatu Selam,1 Andualem Ababu2 1Department of Pharmaceutics and Social Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia; 2Pharmaceutical and Medical Equipment Directorate (PMED), Ministry of ...
Selam MN, Ababu A
doaj